ViaNautis

Biotechnology Research • Cadence, Unity Campus, United Kingdom • 21-50 Employees

Company overview

Headquarters	Cadence, Unity Campus, Cambridge, CB22 3FT, GB
Website	vianautis.com
NAICS	541714
Employees	21-50
Socials

Key Contacts at ViaNautis

Giuseppe Battaglia

Director

Denis Cecchin

Chief Technology Officer

ViaNautis Email Formats

ViaNautis uses 1 email format. The most common is {first name}.{last name} (e.g., john.doe@vianautis.com), used 100% of the time.

Format	Example	Percentage
{first name}.{last name}	john.doe@vianautis.com	100%

About ViaNautis

ViaNautis, formerly known as SomaServe, was founded in 2018 as a spin-off from UCL under the leadership of CEO and serial entrepreneur, Dr Francesca Crawford. The company’s core mission is to create revolutionary genetic medicines, by leveraging polyNaut®’s precision delivery to treat diseases with greater efficacy and improved safety. PolyNaut® is a versatile nano-engineered polymer technology designed for targeted intracellular delivery. This innovative technology enables polymer nanoparticles to deliver a wide range of payloads from small molecules to genetic materials creating ‘a bionic nanoparticle.’ The highly adaptable polymer structure of polyNaut® can be formulated to encapsulate a wide array of genetic cargoes, with sizes exceeding current standards for viral and non-viral delivery. Notably, it enhances the therapeutic efficacy of encapsulated molecules through direct delivery to the cell cytoplasm, facilitated by GOTO® technology for intracellular shuttling. PolyNaut® is set apart from conventional non-viral delivery technologies through its remarkable ability to target specific cells and penetrate biological barriers, including the challenging blood-brain barrier. PolyNaut® nanoparticles, when functionalised for CNS delivery through transcytosis, exhibit exceptional brain uptake. Deploying its state-of-the-art polyNaut® platform, ViaNautis is at the forefront of pioneering new therapies for CNS diseases and cystic fibrosis. The company is actively building an internal pipeline and collaborating with leading pharmaceutical and biotech companies to unlock the potential of promising genetic molecules as well as new therapeutic platforms.

ViaNautis revenue & valuation

Annual revenue	$2,100,000
Revenue per employee	$45,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$6,800,000
Total funding	$24,600,000